Skip to main content
. 2022 Mar 21;11(3):1075–1087. doi: 10.1007/s40121-022-00617-9

Table 4.

Adverse events of favipiravir

Severity Number of cases Probable relevance to favipiravir Cessation of favipiravir Sequelae
Mild 530 (20.9%a) 245 (46.2%) 1 (0.2%) 0 (0%)
Moderate 202 (8.0%a) 119 (58.9%) 0 (0%) 0 (0%)
Serious 3 (0.1%a) 1 (33.3%) 0 (0%) 0 (0%)

Mild: adverse events need no treatment or presented no symptom. Moderate: adverse events need noninvasive treatment. Serious: eminent adverse events need invasive treatment

aDenominators are the total number of cases treated with favipiravir (n = 2532)